Nalfurafine suppresses pruritogen- and touch-evoked scratching behavior in models of acute and chronic itch in mice

Tasuku Akiyama, Mirela Iodi Carstens, Dorothea Piecha, Sonja Steppan, Earl Carstens

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The kappa-opioid agonist, nalfurafine, has been approved in Japan for treatment of itch in patients with chronic kidney disease. We presently investigated if systemic administration of nalfurafine inhibited ongoing or touchevoked scratching behavior (alloknesis) following acute intradermal injection of histamine or the non-histaminergic itch mediator, chloroquine, in mice. We also investigated if nalfurafine suppressed spontaneous or touchevoked scratching in an experimental model of chronic dry skin itch. Nalfurafine reduced scratching evoked by histamine and chloroquine. Following acute histamine, but not chloroquine, low-threshold mechanical stimuli reliably elicited directed hindlimb scratching behavior, which was significantly attenuated by nalfurafine. In mice with experimental dry skin, nalfurafine abolished spontaneous scratching but had no effect on alloknesis. Nalfurafine thus appears to be a promising treatment for acute itch as well as ongoing itch of dry skin.

Original languageEnglish (US)
Pages (from-to)147-150
Number of pages4
JournalActa Dermato-Venereologica
Volume95
Issue number2
DOIs
StatePublished - 2015

Fingerprint

Touch
Chloroquine
Histamine
Skin
Intradermal Injections
Hindlimb
TRK 820
Chronic Renal Insufficiency
Opioid Analgesics
Japan
Theoretical Models
Therapeutics

Keywords

  • Alloknesis
  • Dry skin
  • Itch
  • Mouse
  • Nalfurafine (TRK-820)

ASJC Scopus subject areas

  • Dermatology

Cite this

Nalfurafine suppresses pruritogen- and touch-evoked scratching behavior in models of acute and chronic itch in mice. / Akiyama, Tasuku; Carstens, Mirela Iodi; Piecha, Dorothea; Steppan, Sonja; Carstens, Earl.

In: Acta Dermato-Venereologica, Vol. 95, No. 2, 2015, p. 147-150.

Research output: Contribution to journalArticle

Akiyama, Tasuku ; Carstens, Mirela Iodi ; Piecha, Dorothea ; Steppan, Sonja ; Carstens, Earl. / Nalfurafine suppresses pruritogen- and touch-evoked scratching behavior in models of acute and chronic itch in mice. In: Acta Dermato-Venereologica. 2015 ; Vol. 95, No. 2. pp. 147-150.
@article{34fbc2f919b548848ca07c9c0a13b8f6,
title = "Nalfurafine suppresses pruritogen- and touch-evoked scratching behavior in models of acute and chronic itch in mice",
abstract = "The kappa-opioid agonist, nalfurafine, has been approved in Japan for treatment of itch in patients with chronic kidney disease. We presently investigated if systemic administration of nalfurafine inhibited ongoing or touchevoked scratching behavior (alloknesis) following acute intradermal injection of histamine or the non-histaminergic itch mediator, chloroquine, in mice. We also investigated if nalfurafine suppressed spontaneous or touchevoked scratching in an experimental model of chronic dry skin itch. Nalfurafine reduced scratching evoked by histamine and chloroquine. Following acute histamine, but not chloroquine, low-threshold mechanical stimuli reliably elicited directed hindlimb scratching behavior, which was significantly attenuated by nalfurafine. In mice with experimental dry skin, nalfurafine abolished spontaneous scratching but had no effect on alloknesis. Nalfurafine thus appears to be a promising treatment for acute itch as well as ongoing itch of dry skin.",
keywords = "Alloknesis, Dry skin, Itch, Mouse, Nalfurafine (TRK-820)",
author = "Tasuku Akiyama and Carstens, {Mirela Iodi} and Dorothea Piecha and Sonja Steppan and Earl Carstens",
year = "2015",
doi = "10.2340/00015555-1879",
language = "English (US)",
volume = "95",
pages = "147--150",
journal = "Acta Dermato-Venereologica",
issn = "0001-5555",
publisher = "Society for the Publication of Acta Dermato-Venereologica",
number = "2",

}

TY - JOUR

T1 - Nalfurafine suppresses pruritogen- and touch-evoked scratching behavior in models of acute and chronic itch in mice

AU - Akiyama, Tasuku

AU - Carstens, Mirela Iodi

AU - Piecha, Dorothea

AU - Steppan, Sonja

AU - Carstens, Earl

PY - 2015

Y1 - 2015

N2 - The kappa-opioid agonist, nalfurafine, has been approved in Japan for treatment of itch in patients with chronic kidney disease. We presently investigated if systemic administration of nalfurafine inhibited ongoing or touchevoked scratching behavior (alloknesis) following acute intradermal injection of histamine or the non-histaminergic itch mediator, chloroquine, in mice. We also investigated if nalfurafine suppressed spontaneous or touchevoked scratching in an experimental model of chronic dry skin itch. Nalfurafine reduced scratching evoked by histamine and chloroquine. Following acute histamine, but not chloroquine, low-threshold mechanical stimuli reliably elicited directed hindlimb scratching behavior, which was significantly attenuated by nalfurafine. In mice with experimental dry skin, nalfurafine abolished spontaneous scratching but had no effect on alloknesis. Nalfurafine thus appears to be a promising treatment for acute itch as well as ongoing itch of dry skin.

AB - The kappa-opioid agonist, nalfurafine, has been approved in Japan for treatment of itch in patients with chronic kidney disease. We presently investigated if systemic administration of nalfurafine inhibited ongoing or touchevoked scratching behavior (alloknesis) following acute intradermal injection of histamine or the non-histaminergic itch mediator, chloroquine, in mice. We also investigated if nalfurafine suppressed spontaneous or touchevoked scratching in an experimental model of chronic dry skin itch. Nalfurafine reduced scratching evoked by histamine and chloroquine. Following acute histamine, but not chloroquine, low-threshold mechanical stimuli reliably elicited directed hindlimb scratching behavior, which was significantly attenuated by nalfurafine. In mice with experimental dry skin, nalfurafine abolished spontaneous scratching but had no effect on alloknesis. Nalfurafine thus appears to be a promising treatment for acute itch as well as ongoing itch of dry skin.

KW - Alloknesis

KW - Dry skin

KW - Itch

KW - Mouse

KW - Nalfurafine (TRK-820)

UR - http://www.scopus.com/inward/record.url?scp=84928007739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928007739&partnerID=8YFLogxK

U2 - 10.2340/00015555-1879

DO - 10.2340/00015555-1879

M3 - Article

C2 - 24890341

AN - SCOPUS:84928007739

VL - 95

SP - 147

EP - 150

JO - Acta Dermato-Venereologica

JF - Acta Dermato-Venereologica

SN - 0001-5555

IS - 2

ER -